Indoco Remedies

Indoco Remedies reported a strong Q4 FY26 with consolidated revenue of ₹456 croreCurrent reported value: ₹456 crore. No comparable prior figure is available in the source record., up 18.8% YoYCurrent reported value: 18.8% YoY. No comparable prior figure is available in the source record., driven by a 94.6% surgeCurrent reported value: 94.6% surge. No comparable prior figure is available in the source record. in international formulations, particularly in regulated markets (US +77.5%, Europe +68.7%) and emerging markets (+134%). Domestic formulation revenue declined 6% due to muted seasonal demand for anti-infectives and respiratory products, though prescription growth remained healthy. EBITDA margin improved to 10.9%Current reported value: 10.9%. No comparable prior figure is available in the source record. (vs -0.2% last year) on operating leverage. Management guided for continued international momentum, with US liquid oral approvals and European contract manufacturing scaling up. Key risks include elevated debt (₹960 crore consolidated), stretched receivables from export growth, and the unresolved sterile plant issue limiting future US approvals.